Aviation Medication Transparency Act of 2025
Sponsored By: Representative Casten
In Committee
Summary
Medication transparency for airmen. The Aviation Medication Transparency Act of 2025 would require the FAA to publish and maintain a public, user-friendly list of medications and treatments that may be safely prescribed to an airman for medical certification.
Show full summary
- Airmen (pilots and air traffic controllers) would receive the list when they first seek a license and medical certification. It would identify medications designated as "Do Not Issue" and show any average stabilization periods for limited or no duties.
- Doctors and medical examiners would get a clear reference and a mechanism to contact the FAA with questions about medications and treatments for airmen.
- Pilot and controller bargaining representatives and an aeromedical working group would be consulted while the FAA drafts the list, giving frontline stakeholders input on what is included.
- The FAA would be required to publish the list within 1 year after enactment and update it annually to keep information current.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FAA meds list for pilots and controllers
If enacted, the FAA would post a public list of medicines that airmen can safely use. It would be published no later than 1 year after enactment, then updated within 1 year and every year after. The list would be comprehensive, easy to read, and given to airmen when they first apply for a license and medical certificate. It would show any average time an airman must limit or pause duties to stabilize on a medicine and flag "Do Not Issue" drugs. Doctors would have a direct way to contact the FAA with questions. It would be drafted with input from the Aeromedical Innovation and Modernization Working Group, air traffic controller unions, the main pilot organization, and other relevant stakeholders, and explain what conditions a drug may treat and why some drugs are allowed or banned.
Sponsors & CoSponsors
Sponsor
Casten
IL • D
Cosponsors
Stauber
MN • R
Sponsored 4/2/2025
Rep. Balint, Becca [D-VT-At Large]
VT • D
Sponsored 9/4/2025
Rep. Lawler, Michael [R-NY-17]
NY • R
Sponsored 10/17/2025
McCollum
MN • D
Sponsored 12/9/2025
Rep. McDonald Rivet, Kristen [D-MI-8]
MI • D
Sponsored 12/15/2025
Edwards
NC • R
Sponsored 5/7/2026
Rep. Watson Coleman, Bonnie [D-NJ-12]
NJ • D
Sponsored 5/7/2026
Rep. Ross, Deborah K. [D-NC-2]
NC • D
Sponsored 5/7/2026
Rep. Harder, Josh [D-CA-9]
CA • D
Sponsored 5/12/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov